- Home
- PCRX vs SBGI Comparison
PCRX vs SBGI Comparison
Compare PCRX & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- SBGI
- Stock Information
- Founded
- PCRX 2006
- SBGI 1986
- Country
- PCRX United States
- SBGI United States
- Employees
- PCRX N/A
- SBGI N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- SBGI Broadcasting
- Sector
- PCRX Health Care
- SBGI Industrials
- Exchange
- PCRX Nasdaq
- SBGI Nasdaq
- Market Cap
- PCRX 1.2B
- SBGI 997.6M
- IPO Year
- PCRX 2011
- SBGI 1995
- Fundamental
- Price
- PCRX $22.90
- SBGI $15.09
- Analyst Decision
- PCRX Buy
- SBGI Buy
- Analyst Count
- PCRX 8
- SBGI 5
- Target Price
- PCRX $28.38
- SBGI $18.50
- AVG Volume (30 Days)
- PCRX 545.0K
- SBGI 532.5K
- Earning Date
- PCRX 07-29-2025
- SBGI 08-06-2025
- Dividend Yield
- PCRX N/A
- SBGI 6.61%
- EPS Growth
- PCRX N/A
- SBGI N/A
- EPS
- PCRX N/A
- SBGI 1.97
- Revenue
- PCRX $702,772,000.00
- SBGI $3,526,000,000.00
- Revenue This Year
- PCRX $7.54
- SBGI N/A
- Revenue Next Year
- PCRX $10.78
- SBGI $9.59
- P/E Ratio
- PCRX N/A
- SBGI $7.70
- Revenue Growth
- PCRX 3.08
- SBGI 11.62
- 52 Week Low
- PCRX $11.16
- SBGI $12.07
- 52 Week High
- PCRX $27.64
- SBGI $18.46
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- SBGI 60.64
- Support Level
- PCRX $22.82
- SBGI $14.19
- Resistance Level
- PCRX $23.83
- SBGI $15.78
- Average True Range (ATR)
- PCRX 0.74
- SBGI 0.57
- MACD
- PCRX -0.02
- SBGI 0.22
- Stochastic Oscillator
- PCRX 6.22
- SBGI 73.66
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.